PubRank

Connie Marras

Author PubWeight™ 55.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008 6.76
2 Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011 3.87
3 Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2011 2.92
4 Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015 2.88
5 Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009 2.46
6 Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord 2013 2.32
7 A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord 2008 1.98
8 Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005 1.84
9 Atypical antipsychotics and parkinsonism. Arch Intern Med 2005 1.66
10 Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 2009 1.56
11 Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2012 1.54
12 Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis. Mov Disord 2010 1.48
13 Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology 2014 1.45
14 Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol 2012 1.32
15 Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009 1.16
16 Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012 1.14
17 Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findings. Syst Rev 2012 1.07
18 The curious case of phenocopies in families with genetic Parkinson's disease. Mov Disord 2011 0.96
19 Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. Mov Disord 2007 0.95
20 Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord 2014 0.94
21 Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. Am J Med Genet A 2015 0.91
22 Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord 2012 0.91
23 Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain 2013 0.90
24 Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. Dement Geriatr Cogn Disord 2013 0.87
25 Reply to: Gray et al. Mov Disord 2014 0.84
26 Is there seasonal variation in risk of Parkinson's disease? Mov Disord 2007 0.82
27 Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson's disease? Parkinsonism Relat Disord 2012 0.81
28 Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. J Hum Genet 2011 0.81
29 The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. Mov Disord 2008 0.80
30 Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci 2008 0.78
31 High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005 0.77
32 The pill questionnaire in a nondemented Parkinson's disease population. Mov Disord 2012 0.76
33 A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012 0.76
34 Orthostatic hypotension in Parkinsonism: What is it and how can we treat it? Mov Disord 2015 0.76
35 Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014 0.76
36 Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable. Pharmacoepidemiol Drug Saf 2010 0.76
37 The relevance of pre-motor symptoms in Parkinson's disease. Expert Rev Neurother 2015 0.75
38 Development of a Chronic Care Model for Neurological Conditions (CCM-NC). BMC Health Serv Res 2014 0.75
39 Author reply to Holford, Vu and Nutt regarding 'Piecing together the puzzle of progression and mortality in Parkinson's disease'. Br J Clin Pharmacol 2013 0.75
40 Re: Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 2004 0.75
41 Improvement of apathy after levofloxacin treatment: an N-of-1 study. Neurologist 2012 0.75
42 The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. Parkinsonism Relat Disord 2012 0.75
43 Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force. Mov Disord 2017 0.75
44 Survival and Health Care Use After Deep Brain Stimulation for Parkinson's Disease. Can J Neurol Sci 2020 0.75
45 Current use of domperidone and co-prescribing of medications that increase its arrhythmogenic potential among older adults: a population-based cohort study in Ontario, Canada. Drugs Aging 2014 0.75
46 Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study. Drugs Aging 2013 0.75
47 New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice. Am J Geriatr Psychiatry 2005 0.75